预防癌症疫苗在一次试验中阻止了所有45个林奇综合症携带者的晚期癌症,其中一人凯文·海因克(Kevin Heyink)仍没有患癌症。 A preventive cancer vaccine stopped advanced cancer in all 45 Lynch syndrome carriers in a trial, with one man, Kevin Heyink, remaining cancer-free.

Kevin Heyink, 48岁的安大略警官,是全家唯一一个没有癌症的人,他参加了以林奇综合症为对象的预防性癌症疫苗第1b/2阶段临床试验,这一遗传条件大大增加了结肠切除、内衣检查和其他癌症的风险。 Kevin Heyink, a 48-year-old Ontario police officer, is the only man in his family free of cancer after participating in a phase 1b/2 clinical trial for a preventive cancer vaccine targeting Lynch syndrome, a genetic condition that greatly increases the risk of colorectal, endometrial, and other cancers. 该疫苗由Nouscom研制,在MD Anderson癌症中心测试,使用改良的抗生素病毒对免疫系统进行培训,以针对与综合症有关的异常蛋白。 The vaccine, developed by Nouscom and tested at MD Anderson Cancer Center, uses a modified adenovirus to train the immune system to target abnormal proteins linked to the syndrome. 在接受试验的45个健康林奇综合症携带者中,所有携带者都安全地容忍了疫苗,表现出持久的免疫反应,患先发性损伤的人较少,没有一人患上晚期癌症。 Of 45 healthy Lynch syndrome carriers in the trial, all tolerated the vaccine safely, showed lasting immune responses, developed fewer precancerous lesions, and none developed advanced cancer. 在《自然医学》上发表的结果突显了疫苗作为遗传癌症风险预防工具的潜力,为降低高危人群早期发癌提供了希望。 Results published in Nature Medicine highlight the vaccine’s potential as a preventive tool for inherited cancer risks, offering hope for reducing early-onset cancers in high-risk individuals.